Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Preventing Postoperative Recurrence in Crohn's Disease
NCT03185624Phase 3Unknown
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Jul 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of rifaximin in Crohn's disease (2 arms), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Rate of Endoscopic Recurrence at 6 months. Status: unknown.
02
Drugs
rifaximin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03185624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03185624.